<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880162</url>
  </required_header>
  <id_info>
    <org_study_id>CaPrO</org_study_id>
    <nct_id>NCT03880162</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of a Low Carbohydrate Versus a Standard Diet in Morbidly Obese With Prediabetes</brief_title>
  <acronym>CaPrO</acronym>
  <official_title>Metabolic Effects of a Low Carbohydrate Versus Energy-matched Standard Diet in Morbidly Obese Individuals With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the metabolic effects of a low carbohydrate versus energy-matched standard
      diet in morbidly obese individuals with prediabetes awaiting bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metabolic benefits of calorie restriction in obese people with or without impaired
      glycaemia are well-established. The impact of diet composition, however, remains poorly
      understood. Hepatic lipid content strongly correlates with hepatic insulin resistance, which
      is a key feature of the pre-diabetic state. The investigators hypothesize that a low
      carbohydrate diet compared to an energy-matched standard diet in morbidly obese patients with
      prediabetes scheduled for bariatric surgery results in greater reduction in liver fat.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-centre, randomized parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in intrahepatic triglyceride content</measure>
    <time_frame>2 weeks</time_frame>
    <description>The intrahepatic triglyceride content will be evaluated by magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>2 weeks</time_frame>
    <description>The body weight will be measured using a pre-defined person scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver size</measure>
    <time_frame>2 weeks</time_frame>
    <description>The liver size will be evaluated by magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in visceral adipose tissue</measure>
    <time_frame>2 weeks</time_frame>
    <description>The adipose tissue content will be evaluated by magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in whole body fat mass</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fat mass will be evaluated by bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin secretion</measure>
    <time_frame>2 weeks</time_frame>
    <description>The insulin secretion will be evaluated during an oral glucose tolerance test using the oral minimal model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin sensitivity</measure>
    <time_frame>2 weeks</time_frame>
    <description>The insulin sensitivity will be evaluated during an oral glucose tolerance test using the oral minimal model</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in plasma metabolome</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fasting serum sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in plasma transcriptome</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fasting serum sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Fibroblast Growth Factor 21</measure>
    <time_frame>2 weeks</time_frame>
    <description>Plasma level</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in adipose tissue inflammation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Adipose tissue histology</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in gut microbiota composition</measure>
    <time_frame>2 weeks</time_frame>
    <description>Distribution of the predominant bacterial phylotypes will be assessed after 16S rRNA amplicon sequencing and subsequent taxonomic classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline levels of secondary bile acids</measure>
    <time_frame>2 weeks</time_frame>
    <description>Faecal sampling</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in frequency of immune cells (T-, B-, NK-cells, monocytes, neutrophils)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Frequency of immune cells will be analysed using flowcytometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in immunometabolism of T-cells</measure>
    <time_frame>2 weeks</time_frame>
    <description>Immunometabolism will be assessed by quantifying rates of oxygen consumption and glycolysis using metabolic flux analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of surgical complication</measure>
    <time_frame>Day of surgery until 2 weeks post-surgery</time_frame>
    <description>Occurrence of the following: anastomotic leak, infection, bleeding, deep venous thrombosis (based on medical records)</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Day of surgery until 2 weeks post-surgery</time_frame>
    <description>Based on medical records</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Study intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)</description>
    <arm_group_label>Study intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Energy-matched standard diet</intervention_name>
    <description>Energy-matched (30% deficit) standard diet (50% of carbohydrates)</description>
    <arm_group_label>Control intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male subjects aged 18 years or older

          -  BMI &gt;35 kg/m2 awaiting bariatric surgery

          -  Pre-diabetes according to American Diabetes Association criteria (HbA1c 5.7%-6.4%)

          -  Capacity to give informed consent and adhere to study procedures

        Exclusion Criteria:

          -  Excess alcohol consumption (&gt; 3 units/day for men, &gt; 2 units/day for women)

          -  Moderate to severe kidney disease

          -  Nephrolithiasis

          -  Pregnancy/breastfeeding

          -  Current participation in another clinical trial

          -  Claustrophobia

          -  MRI-contraindications (pacemaker/defibrillator, neurostimulator, drug pump, cochlear
             implant, heart valve/vascular clips, shunt valve)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lia Bally, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital, Bern University Hospital, University of Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lia Bally, MD PhD</last_name>
    <phone>+41 (0)31 632 36 77</phone>
    <email>lia.bally@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Bally, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Low-carb diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

